腰椎椎間板変性疾患市場：治療法、投与経路、エンドユーザー別-2025～2030年の世界予測

腰椎椎間板変性疾患市場は、2023年に7億4,458万米ドルと評価され、2024年には7億9,633万米ドルに達すると予測され、CAGR 7.15%で成長し、2030年には12億776万米ドルに達すると予測されています。

腰椎椎間板変性疾患（LDDD）は、腰椎の椎間板の劣化を特徴とする疾患で、慢性的な痛みを引き起こします。高齢化や座りっぱなしの人の間でこの疾患の有病率が上昇していることから、効果的な治療法や技術に対する需要が高まっています。市場範囲には、外科的介入、生物学的療法、再生医療や低侵襲処置のような新しい技術によるソリューションが含まれます。背中や首の痛みは、医師の診察や欠勤の理由の上位に挙げられており、病院から外来手術センターまで医療セグメントでの応用を促進しています。個別化された費用対効果の高い治療へのニーズは、患者中心のケアモデルに焦点を当てることで、最終用途をさらに導いています。主要成長要因としては、脊髄装置や再生医療における技術的進歩、医療支出の増加、利用可能な治療法に対する患者の意識の高まりなどが挙げられます。治療機会は、より低侵襲で効果的な治療の可能性を示す革新的な生体材料や幹細胞ベースの製品のような再生治療の採用にあります。開発企業は、医療インフラが急速に発展している新興国市場で地理的プレゼンスを拡大しながら、痛みを和らげ病気の進行を食い止めるための非外科的治療を推進する動向を活用すべきです。逆に、市場成長の制約としては、高額な手術費用や新しい医療技術に伴う規制の複雑さなどが挙げられます。また、理学療法やカイロプラクティックなどの代替治療との競合も課題となりえます。技術革新が必要なセグメントとしては、次世代生物製剤の開発、より良い診断のための高度画像診断、継続的モニタリングのための患者に優しいウェアラブル技術などがあります。企業は、新規治療法の受容を促進するため、研究提携や患者教育に投資すべきです。市場はダイナミックな性質を維持しており、新規参入のための強力なパイプラインと、技術的進歩と世界人口の高齢化による需要増加の両方によって、大幅な成長の余地があります。

市場力学：急速に進化する腰椎椎間板変性疾患市場の主要市場洞察を公開

腰椎椎間板変性疾患市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 腰椎椎間板変性疾患の普及拡大
  • LDDDに関する啓発キャンペーンと教育の高まり
• 市場抑制要因
  • 保険償還の制限
• 市場機会
  • 新たなLDDD治療・診断の導入に向けた継続的な研究開発
  • LDDD治療の商業化に向けた政府の好意的な承認
• 市場課題
  • 外科手術と医薬品開発の複雑さ

ポーターのファイブフォース：腰椎椎間板変性疾患市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：腰椎椎間板変性疾患市場における外部からの影響の把握

外部マクロ環境要因は、腰椎椎間板変性疾患市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：腰椎椎間板変性疾患市場における競合情勢の把握

腰椎椎間板変性疾患市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：腰椎椎間板変性疾患市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、腰椎椎間板変性疾患市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：腰椎椎間板変性疾患市場における成功への道筋を描く

腰椎椎間板変性疾患市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 腰椎椎間板変性疾患の普及率の増加
    • LDDDに関する啓発キャンペーンと教育の拡大
  • 抑制要因
    • 払い戻しの利用可能範囲が限られている
  • 機会
    • LDDDの新たな治療法と診断法の導入に向けた継続的な研究開発
    • LDDD薬の商業化に対する政府の好意的な承認
  • 課題
    • 外科手術と医薬品開発の複雑さ
• 市場セグメンテーション分析
  • 治療：腰椎椎間板変性疾患の管理のための硬膜外ステロイド注射（ESI）の使用の増加
  • エンドユーザー：患者の診断、治療、管理のための腰椎椎間板変性疾患治療の必要性が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 腰椎椎間板変性疾患市場：治療別

• イントロダクション
• 硬膜外ステロイド注射（ESI）
• 市販の鎮痛剤
  • アセトアミノフェン
  • 抗炎症薬
  • コルチコステロイド
  • 筋弛緩剤
  • 麻薬
• 治療機器

第7章 腰椎椎間板変性疾患市場：投与経路別

• イントロダクション
• 注射
• 経口

第8章 腰椎椎間板変性疾患市場：エンドユーザー別

• イントロダクション
• 学術研究センター
• 病院・クリニック
• 専門クリニック

第9章 南北アメリカの腰椎椎間板変性疾患市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の腰椎椎間板変性疾患市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの腰椎椎間板変性疾患市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • FDAがReGelTecのHYDRAFILシステムを腰椎椎間板変性疾患の治療として承認
  • RITの研究者が腰椎変性疾患に対するCRISPR強化幹細胞療法にNIH助成金を授与
  • Companion Spine、バックボーンSASの戦略的買収により世界の脊椎医療を推進
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AnGes MG, Inc.
• AxioMed LLC
• B. Braun SE
• Baxter International Inc.
• Benvenue Medical, Inc.
• Biopharm GmbH
• Boston Scientific Corporation
• Centinel Spine, LLC
• Cerapedics Inc.
• ChoiceSpine
• DePuy Synthes by Medical Device Business Services, Inc.
• Globus Medical, Inc.
• Kolon TissueGene Inc.
• Kuros Biosciences
• Lineage Cell Therapeutics, Inc.
• Medtronic plc
• NLC Ventures Netherlands B.V.
• Notogen, Inc.
• Orthofix Medical Inc.
• RTI Surgical Holdings, Inc.
• Stryker Corporation
• Ulrich Medical USA Inc.
• Veritas Health, LLC
• Xtant Medical Holdings, Inc.
• Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

• FIGURE 1. LUMBAR DEGENERATIVE DISC DISEASE MARKET RESEARCH PROCESS
• FIGURE 2. LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. LUMBAR DEGENERATIVE DISC DISEASE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. LUMBAR DEGENERATIVE DISC DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LUMBAR DEGENERATIVE DISC DISEASE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LUMBAR DEGENERATIVE DISC DISEASE MARKET DYNAMICS
• TABLE 7. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY EPIDURAL STEROID INJECTIONS (ESIS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY MUSCLE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY NARCOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY THERAPY DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 37. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 38. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 39. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 59. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 61. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 63. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 64. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 65. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 132. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 133. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 134. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 148. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 149. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 150. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 152. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 153. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 154. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 192. LUMBAR DEGENERATIVE DISC DISEASE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 193. LUMBAR DEGENERATIVE DISC DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

The Lumbar Degenerative Disc Disease Market was valued at USD 744.58 million in 2023, expected to reach USD 796.33 million in 2024, and is projected to grow at a CAGR of 7.15%, to USD 1,207.76 million by 2030.

Lumbar Degenerative Disc Disease (DDD) is a condition characterized by the deterioration of the intervertebral discs in the lumbar spine, causing chronic pain. The rising prevalence of this ailment among aging populations and sedentary individuals propels demand for effective treatments and technologies. The market scope encompasses surgical interventions, biological therapies, and emerging technology-based solutions like regenerative medicine and minimally invasive procedures. A significant necessity drives this market; back and neck pain is among the top reasons for physician visits and absenteeism from work, fostering applications in healthcare sectors from hospitals to outpatient surgical centers. The need for personalized, cost-effective treatments further guides end-use by focusing on patient-centric care models. Key growth factors include technological advancements in spinal devices and regenerative medicine, increasing healthcare expenditures, and growing awareness of available treatments among patients. Opportunities lie in the adoption of innovative biomaterials and regenerative therapies, like stem cell-based products, which show potential for less invasive and more effective treatments. Commercial entities should capitalize on trends promoting non-surgical therapies designed to alleviate pain and halt the disease's progression while broadening their geographical presence in emerging markets where healthcare infrastructure is developing rapidly. Conversely, market growth constraints include high procedure costs and the regulatory complexities associated with new medical technologies. Competition from alternative treatments such as physical therapy and chiropractic interventions may also pose challenges. Areas ripe for innovation include the development of next-generation biologics, advanced imaging for better diagnosis, and patient-friendly, wearable technologies for continuous monitoring. Businesses should invest in research partnerships and patient education to foster acceptance of novel therapies. The market maintains a dynamic nature with a robust pipeline for new entrants and substantial room for growth, driven by both technological advancements and a demand increase prompted by an aging global population.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lumbar Degenerative Disc Disease Market

The Lumbar Degenerative Disc Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of lumbar degenerative disc disease
  • Rising awareness campaigns and education about LDDD
• Market Restraints
  • Limited availability of reimbursement
• Market Opportunities
  • Ongoing R&D for introducing new LDDD treatments and diagnosis
  • Favorable government approvals for LDDD medicine commercialization
• Market Challenges
  • Complexity in surgical procedures and medicine development

Porter's Five Forces: A Strategic Tool for Navigating the Lumbar Degenerative Disc Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lumbar Degenerative Disc Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lumbar Degenerative Disc Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lumbar Degenerative Disc Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lumbar Degenerative Disc Disease Market

A detailed market share analysis in the Lumbar Degenerative Disc Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lumbar Degenerative Disc Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lumbar Degenerative Disc Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lumbar Degenerative Disc Disease Market

A strategic analysis of the Lumbar Degenerative Disc Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lumbar Degenerative Disc Disease Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AnGes MG, Inc., AxioMed LLC, B. Braun SE, Baxter International Inc., Benvenue Medical, Inc., Biopharm GmbH, Boston Scientific Corporation, Centinel Spine, LLC, Cerapedics Inc., ChoiceSpine, DePuy Synthes by Medical Device Business Services, Inc., Globus Medical, Inc., Kolon TissueGene Inc., Kuros Biosciences, Lineage Cell Therapeutics, Inc., Medtronic plc, NLC Ventures Netherlands B.V., Notogen, Inc., Orthofix Medical Inc., RTI Surgical Holdings, Inc., Stryker Corporation, Ulrich Medical USA Inc., Veritas Health, LLC, Xtant Medical Holdings, Inc., and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Lumbar Degenerative Disc Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment, market is studied across Epidural Steroid Injections (ESIs), Over-the-counter (OTC) Pain Medications, and Therapy Devices. The Over-the-counter (OTC) Pain Medications is further studied across Acetaminophen, Anti-inflammatories, Corticosteroids, Muscle Relaxants, and Narcotics.
• Based on Route of Administration, market is studied across Injectables and Oral.
• Based on End-Users, market is studied across Academic Research Centers, Hospitals & Clinics, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of lumbar degenerative disc disease
    • 5.1.1.2. Rising awareness campaigns and education about LDDD
  • 5.1.2. Restraints
    • 5.1.2.1. Limited availability of reimbursement
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D for introducing new LDDD treatments and diagnosis
    • 5.1.3.2. Favorable government approvals for LDDD medicine commercialization
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity in surgical procedures and medicine development
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment: Rising usage of epidural steroid injections (ESIs) for management of lumbar degenerative disc disease
  • 5.2.2. End-Users: Increasing need for lumbar degenerative disc disease treatment for diagnosing, treating, and managing patients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Lumbar Degenerative Disc Disease Market, by Treatment

• 6.1. Introduction
• 6.2. Epidural Steroid Injections (ESIs)
• 6.3. Over-the-counter (OTC) Pain Medications
  • 6.3.1. Acetaminophen
  • 6.3.2. Anti-inflammatories
  • 6.3.3. Corticosteroids
  • 6.3.4. Muscle Relaxants
  • 6.3.5. Narcotics
• 6.4. Therapy Devices

7. Lumbar Degenerative Disc Disease Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectables
• 7.3. Oral

8. Lumbar Degenerative Disc Disease Market, by End-Users

• 8.1. Introduction
• 8.2. Academic Research Centers
• 8.3. Hospitals & Clinics
• 8.4. Specialty Clinics

9. Americas Lumbar Degenerative Disc Disease Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Lumbar Degenerative Disc Disease Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Lumbar Degenerative Disc Disease Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. FDA Clears ReGelTec's HYDRAFIL System for Treatment of Lumbar Degenerative Disc Disease
  • 12.3.2. RIT Researchers Awarded NIH Grant to CRISPR-Enhanced Stem Cell Therapy for Lumbar Degeneration
  • 12.3.3. Companion Spine Advances Global Spine Health with Strategic Acquisition of Backbone SAS
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AnGes MG, Inc.
• 3. AxioMed LLC
• 4. B. Braun SE
• 5. Baxter International Inc.
• 6. Benvenue Medical, Inc.
• 7. Biopharm GmbH
• 8. Boston Scientific Corporation
• 9. Centinel Spine, LLC
• 10. Cerapedics Inc.
• 11. ChoiceSpine
• 12. DePuy Synthes by Medical Device Business Services, Inc.
• 13. Globus Medical, Inc.
• 14. Kolon TissueGene Inc.
• 15. Kuros Biosciences
• 16. Lineage Cell Therapeutics, Inc.
• 17. Medtronic plc
• 18. NLC Ventures Netherlands B.V.
• 19. Notogen, Inc.
• 20. Orthofix Medical Inc.
• 21. RTI Surgical Holdings, Inc.
• 22. Stryker Corporation
• 23. Ulrich Medical USA Inc.
• 24. Veritas Health, LLC
• 25. Xtant Medical Holdings, Inc.
• 26. Zimmer Biomet Holdings, Inc.